Warner-lambert Company

Other

Annette M Doherty

Joseph Thomas Repine

Ila Sircar

William Chester Patt

Harriet W Hamilton

Jeremy John Edmunds

Kent A Berryman

James S Kaltenbronn

Xue-min Cheng

Daniele Marie Leonard

James Marino Hamby

Wayne Livingston Cody

Cleo Connolly

Clifton J Blankley

Robert Lee Panek

John C Hodges

Sylvester R Klutchko

Sham Shridhar Nikam

Dennis Joseph McNamara

Brian Edward Kornberg

John Quin, Iii

Michael D Taylor

John Xiaoqiang He

Patricia DePue

Diane H Boschelli

Mel C Schroeder

Chitase Lee

Edward Faith Elslager

Howard D Showalter

Leslie M Werbel

Amy Mae Bunker

Mark Stephen Plummer

Kevon Ray Shuler

Judith Sebolt-Leopold

Kyunghye Ahn

Jeffrey D Scholten

Harold Zinnes

Gary Louis Bolton

David Charles Rees

Francis John Tinney

William Howard Roark

John G Topliss

Ellen Myra Dobrusin

James P Hudspeth

M Arshad Siddiqui

Bruce Allan Steinbaugh

Janet S Plummer

John X He

Hussein Osman Hallak

Inhibitors of protein farnesyl transferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.

Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase

Novel nonpeptide endothelin I antagonists of Formula

Nonpeptide endothelin antagonists with increased water solubility

A process for the preparation of novel keto heterocycle derivatives of basic natural and unnatural amino acids which affords products of high enantiomeric excess where a metalated heterocycle is reacted with N,O-dialkyl amide of an amino acid containing arylsulphonamide protected side chain amine in high chemical and optical yield as well as the novel compounds obtained by the process.

Process for the preparation of chiral keto-heterocycles of basic amino acids

Novel inhibitors of protein farnesyltransferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer, restenosis, atherosclerosis, psoriasis and endometriosis.

Cycloalkyl inhibitors of protein farnesyltransferase

The present invention provides compounds having the structure represented by formula (I). Also provided is a method of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compound of formula (I).

Dipeptide inhibitors of protein farnesyltransferase

Endothelin antagonists with ether-linked groups

Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors

Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.

Nonpeptide endothelin antagonists I

Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine

Furanone endothelin antagonists

6-Aryl naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.

6-aryl naphthyridines for inhibiting protein tyrosine kinase mediated

N-oxides of amino containing 6-aryl pyrido�2,3-d!-pyrimidine 7-imines, 7-ones, and 7-thiones have the formula ##STR1## where A and B are linkers, Ar is aryl, R.sub.2 is aklyl, X is O, S, or NH, or NAcyl, and R.sub.5 and R.sub.6 are alkyl. The compounds are inhibitors of protein tyrosine kinases and cyclin-dependent kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.

N-oxides of amino containing pyrido �2,3-D! pyrimidines

Antagonists of endothelin are described, as well as methods of using them and pharmaceutical compositions containing them. These compounds are useful in controlling hypertension, myocardial infarction, pulmonary hypertension, angina, metabolic, endocrinological, and neurological disorders, congestive heart failure, septic or endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, preeclampsia, and diabetes.

Endothelin antagonists

Tricyclic inhibitors of protein farnesyltransferase

Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.

Growing community of inventors

Ann Arbor, MI, United States of America

Annette M Doherty